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Abstract Hyperlipidemic myeloma is a rare and poorly
understood variant of multiple myeloma. We report the case
of a 53-year-old woman with hyperlipidemic myeloma,
skin xanthomas and hyperviscosity syndrome who under-
went allogeneic bone marrow transplantation. A compre-
hensive literature search identified 52 additional cases with
plasma cell disease and hyperlipidemia. A detailed analysis
revealed several characteristics of these patients as compared
to multiple myeloma with normal lipid status: (1) IgA
paraprotein was present in the majority (53% vs. 21% in
classical multiple myeloma). (2) Skin xanthomas, especially
in the palmar creases, elbows, and knees were common
(70%). (3) Hyperviscosity syndrome occurred more often
(26% vs. 2–6%). While conventional lipid-lowering therapy
had only marginal effects, successful anti-myeloma therapy
also reduced hyperlipidemia. Analyses of the mechanisms
leading to hyperlipidemia documented complexes of para-
protein and lipoprotein in 75% of the 32 cases tested,
suggesting an inhibitory role of the paraprotein on lipid
degradation. In conclusion, the clinical characteristics, the
therapeutic options, and the pathophysiologic mechanisms of
hyperlipidemic myeloma are comprehensively reported using
the available data from all 53 published cases in the literature.
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Introduction
Hyperlipidemic myeloma (HLM) is a rare variant of
multiple myeloma [4]. While it may present as an isolated
laboratory finding, in some cases it is associated with skin
xanthomas and/or hyperviscosity syndrome, dominating the
clinical picture. Since previous comprehensive reports of
HLM date back 30 years [4, 11, 43, 52, 63] and due to its
low incidence, symptoms, the clinical course, and the best
therapy of HLM remain largely unknown. Even though the
unusual lipid patterns, occasionally manifesting as a grossly
lipemic and highly viscous serum were studied extensively
in some cases, the underlying mechanism of HLM remains
unknown. According to one hypothesis, the paraprotein
binds to lipoproteins and, thereby, inhibits their degradation
[2, 4, 6, 13, 37, 63]. This view has been challenged, and
evidence for an affinity of the paraprotein to heparin or the
low-density lipoprotein (LDL) receptor was provided,
leaving the matter open for debate [12, 13, 52, 66]. Here,
we present a patient with HLM who was treated with
allogeneic bone marrow transplantation, as well as an
extensive literature research revealing a total of 52 additional
cases.
Case presentation
In 2003, a 53-year-old woman with HLM was referred for
allogeneic hematopoietic stem cell transplantation; the time
course of events is shown in Fig. 1. The patient had been
well until 1993, when pain in both shoulders and the neck
accompanied by an elevated erythrocyte sedimentation rate
(ESR) occurred. A paraprotein (IgAκ, 5.95 g/l, normal
range 0.7–4) was discovered and her bone marrow was
infiltrated by 15–20% atypical plasma cells. Peripheral
blood count, calcium, creatinine, β2-microglobulin levels,
and bone scan were unremarkable. A diagnosis of smoldering
multiple myeloma was made. In March 1999, orange skin
xanthomas were noted in the folds of the hands and feet and at
the surface of the fingers below her rings (pressure points).
The myeloma had progressed, causing anemia with a
hemoglobin of 10.3 g/dl, the IgA level was 25.1 g/l with a
β2-microglobulin of 2.75 mg/l (<2.4), and the ESR was
110 mm/h. Elevated cholesterol levels (11 mmol/l, <5.2) were
treated with simvastatine and subsequently with atorvastatine
and quantalan without success. Skin biopsy demonstrated the
presence of foam cells in the upper corium. The patient was
not obese (170 cm, 78 kg, body mass index: 27 kg/m2) and
free of cardiovascular complaints. There were no cardiac risk
factors besides a history of smoking; electrocardiography,
stress test, and echocardiography were normal. The family
history for hyperlipidemia and xanthomas was negative. In
the summer of 2001, the patient reported headache, blurred
vision, and gait instability indicating hyperviscosity syn-
drome. Examination of the ocular fundus revealed dilated
segmented veins, cotton wool spots, and ocular bleeding.
Skin xanthomas now also involved the thighs, knees, and the
forearms. Anemia had progressed, and the bone marrow was
now infiltrated by 35% atypical plasma cells. IgA had risen
to 39.4 g/l, total protein to 98 g/l, and cholesterol to
16.2 mmol/l. Four cycles of chemotherapy with vincristine,
adriblastin, and dexamethason were applied and stabilized
the myeloma parameters without having an effect on the
lipid levels (triglycerides 17.8 mmol/l and cholesterol
24 mmol/l). In contrast, three sessions of plasmapheresis in
addition to a single dose of cyclophosphamide decreased the
levels of triglycerides and cholesterol to 11.6, mmol/l, and
7.8 mmol/l, respectively, and promptly relieved the symp-
toms of hyperviscosity. Peripheral stem cells were collected,
and two autologous stem cell transplantations were performed
after melphalan conditioning in February and August 2002.
Thereafter, lipid and IgA levels returned to normal with a
concurrent resolution of the skin xanthomas until January
2003. However, because the paraprotein started to rise again
in spring 2003, the patient underwent allogeneic stem cell
transplantation from a human leukocyte antigen (HLA)
identical brother, following a reduced intensity conditioning
regiment in April 2003. Shortly thereafter, a rise in para-
protein and lipid levels, associated with hyperviscosity
syndrome, was successfully treated with thalidomide and
high doses of dexamethasone, as well as three sessions of
plasmapheresis. The patient remained free of symptoms for
8 months before myeloma relapsed with bone lesions of the
skull. Palliative radiation, bortezomib therapy, and three
cycles of dexamethasone, thalidomide, cisplatin, doxorubi-
cin, cyclophosphamide, and etoposide (DT-PACE) were
applied. Hyperviscosity syndrome necessitated biweekly
plasmapheresis. In 2006, intractable bone pain developed,
and posterior leucencephalopathy caused an incomplete left-
sided paresis. After consultation with the patient and her
family, no further therapeutic attempts were made, and the
patient died. Permission to conduct necropsy was not
granted, but post mortem DNA analysis of a bone marrow
biopsy revealed a normal E3/E3 apolipoprotein E genotype.
Patients and methods
A PubMed search was carried out using the search terms
“hyperlipidemia”, “hypertriglyceridemia” or “hypercholes-
terolemia”, “multiple myeloma”, and “paraproteinemia” or
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“paraprotein”. Case reports published until June 2007
written in English, French, Spanish, German, Russian, and
Czech fulfilling both of the following criteria were included:
(1) paraproteinemia or an abnormal plasma cell clone in bone
marrow or tissue biopsy; (2) hypertriglyceridemia >5 mmol/
l or hypercholesterolemia >8.5 mmol/l. These high threshold
values were chosen arbitrarily to exclude dyslipidemia of
metabolic syndrome. Plasma cell disease was classified
following international guidelines [29, 47] as monoclonal
gammopathy of unknown significance (MGUS), multiple
myeloma, or smoldering multiple myeloma. Since many
reports lacked complete documentation of end organ damage,
a plasma cell count of >30%, extensive bone marrow
infiltration or pronounced atypia were also considered
diagnostic for multiple myeloma. Complete remission (CR)
for myeloma was defined as lack of any evidence of myeloma
after treatment; partial remission (PR) required marked
decrease of the paraprotein level. Similarly, CR required a
normalization, and PR a marked improvement of lipid levels.
Statistical analysis was carried out using Graphpad Prism®
and included linear regression, Fisher’s exact test, Mann-
Whitney testing, and a survival analysis tool. Due to the fact
that this meta-analysis contains incomplete data sets, p values
have to be interpreted with caution.
Results
Baseline characteristics and laboratory values A total of
52 additional cases of HLM published between 1937 and
2007 were identified (Table 1). The majority (85%) fulfilled
the criteria of multiple myeloma; in addition, four cases
(7.5%) were classified as smoldering myeloma and four
cases as MGUS (Table 2). Overall, these patients differed
from a large published myeloma cohort [35] by a
predominance of IgA myeloma (53.3% vs 21%), while
IgG (42% vs. 51.5%) light chain and nonsecreting
myeloma (0% vs 3% and 20%, respectively) were under-
represented. In contrast, the distribution of kappa- and
lambda myeloma was identical. HLM patients were slightly
younger at diagnosis (57 years, range 21–74 vs 66 years
old, range 20–92), and a slight male preponderance (30
cases vs. 23) was noted.
The median triglyceride value was 11.5 mmol/l (range
2.4–65.7) and the median cholesterol level 16.5 mmol/
l (3.5–49.2). Cholesterol levels of patients with IgA
myeloma were higher than with IgG myeloma (Fig. S1).
A striking correlation between paraprotein and lipid
concentrations was observed in our patient (R2=0.84 and
0.74 for cholesterol and triglycerides, respectively, Fig. S2),
in line with similar longitudinal data reported for 12
additional patients. Additional conditions aggravating
hyperlipidemia were present in seven patients including
nephrotic syndrome (four), diabetes mellitus (two), and
hypothyroidism (one). The serum was reported to be milky,
turbid, oily, or lipemic in 24 cases, sometimes with a
creamy cap.
Clinical presentation Typically, symptoms of hyperlipidemia
or xanthomas preceded the diagnosis of plasma cell disease in
21 and 22 cases, respectively, sometimes by more than
10 years (mean delay 4.1 and 3.6 years, respectively,
Table S1). In other patients, plasma cell disease was
diagnosed simultaneously (23 and four cases) or even before
(five and three cases) the hyperlipidemic and xanthoma
symptoms. Skin xanthomas were described in 37 of 53
patients (70%), typically, the palmar creases of the hands
were involved, but the periorbital region, elbows, and knees
were also concerned (Table S2). In general, xanthomas were
painless; however, for five patients, painful lesions dominated
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Fig. 1 Time course of events
for our patient with HLM.
Values for paraprotein, IgA,
cholesterol and triglycerides are
given, anti-myeloma treatments
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thalidomide, cisplatin,
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Table 1 Fifty-three patients with HLM
Year of
publication
Sex Agea Diagnosisb Paraprotein g/l TGL
(mmol/l)
Cholesterol
(mmol/l)
Reference Atherosclerosis Skin
xanthomas
2009 F 43 MM (sMM) IgA κ 34.4 34.7 31.1 This paper no yes, HKEFOP
2005 M 48 MM IgG l 72d 9.5 16.5 [9] no no
2005 M 72 MM IgA κ 33.6 16.4 28.6 [8] no yes, HEF
1997 F 50 MM IgA κ 26.1d 11.9 29.7 [45, 68] no yes, HKETF
1997 F 51 MGUS IgG κ 23 5.5 14.6 [31] no yes, KFO
1996 F 70 MM IgA κ 34d 5.2 15.5 [21] TIA no
1996 M 52 MGUS IgG κ 22 6.2 6.2 [60] no yes, HEO
1995 F 61 MM IgG ? 7.3 3.7 [67] no yes, TD
1992 F 58 MM IgA κg 20.5 18.5 [17] no yes, TF
1992 M 85 MM IgG κ 49.9d 10.5 20.2 [1] no no
1991 F 42 sMM IgM l 12.3d 11.7 16.7 [25] no yes, H
1990 F 58 MM IgA l 63.6d 8.7 11.8 [18] no yes, HEO
1988 F 48 MM IgA κ 6.5d 35.9 33.7 [16] no no
1987 F 49 MM (MGUS) IgG l 33.6d 7.7 13.3 [20] no yes, HO
1986 M 42 MM IgG κc 90 4.4 11 [53] MI no
1986 M 31 MGUS IgA κ ? 2.4 23.3 [12] MI yes, E
1985 M 72 MM IgA κ 27d 40.9 35.5 [32] no no
1982 M 52 MM IgA κ 31d 26.3 34.1 [13] PAD yes, HKEFO
1982 M 50 MM IgG κ 54d 10.9 5.6 [13] no yes, H
1982 F 58 MM IgA l 35d 12.4 49.2 [24] no yes, HKETFDP
1982 M 53 MM IgG l 5.7d 28.5 7.4 [48] ? no
1979 M 50 MM IgD l 3.5d 27.1 n.a. [49] no no
1979 F 57 MM IgA l 72.9 4.3 16.3 [15] no yes, HKEO
1978 M 64 MM IgA l 30 12.8 20.4 [64] no yes, HEO
1978 F 69 MM IgG l 30 8 10.6 [23] no no
1978 F 69 MM IgG κ 28d 12.7 20.4 [63] no yes, HD
1975 M 59 sMM IgA l 34d 26.3 32.4 [27, 37] PAD yes, ET
1975 M 31 MM IgG κ 18d 4.9 14.8 [66] MI yes, O
1975 F 57 MM IgG l ? 2.6 12.6 [39] no yes, HTFO
1975 M 60 MM IgA κ 7d 6.8 11.4 [52] no yes, HKET
1972 M 60 MM IgG l 56e 11.3 n.a. [22] MI, PAD no
1972 F n.a. MM IgG ? 120f 12.7 31.6 [10] no yes, HETOP
1972 F 41 MGUS IgG κ 28.4d 5.3 7.3 [33] no yes, TFO
1971 M 60 MM IgG ? 3.6 8.6 [56] no yes, O
1970 M 49 MM IgG l 38d 7.3 9.7 [42, 43] no yes, HTFD
1970 M 50 sMM IgA ? n.a. 14.3 [46] SCD no
1968 F 42 MM IgA ? 58d 22.6 41.4 [30] no yes, EFDP
1968 M 59 MM IgA ? 16.3 3.5 [62] no no
1967 M 57 MM IgA κ 45.6 16.3 25.6 [5, 6] MI yes, HTOD
1967 M 62 MM IgA κ 92f 20.8 29 [2, 5] PAD yes, E
1967 M 41 MM IgA ? 18.5d 9.3 18.5 [54] no no
1966 F 56 MM IgG l ? 11.6 25.9 [11] no yes, HETFP
1965 M 52 MM n.a. ? n.a. 8.7 [58] no yes, O
1965 F 68 MM IgA ? 25.8e 28.5 45.8 [55] MI yes, KE
1964 M 46 MM β-2 ? n.a. 30.8 [44] MI yes, HEP
1964 M 56 sMM γ-type ? n.a. 8.4 [40] no yes, FO
1963 F 53 MM γ-type ? n.a. 9.8 [28] no no
1961 M 59 MM γ-type ? n.a. 13.9 [19] no yes, TFO
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the clinical picture. In five cases (including ours), xanthomas
developed preferentially below pressure points, for instance in
the region below the rings of the fingers or the brassiere. Skin
biopsies were performed in 21 cases and showed uniformly
foam cells, sometimes together with a lymphocytic infiltrate.
Immunoglobulin deposition was detected in one skin biopsy
and one surgical sample of an artery, four skin biopsies tested
negative for immunoglobulins. Hyperviscosity syndrome
occurs in 2–6% of myeloma patients [41], but developed in
14 HLM patients (26%) causing symptoms of bleeding in
five patients including two with retinal hemorrhage, ischemia
of the lower limbs (two) or abdominal organs (three). Mental
changes were noted in eight patients including symptoms of
confusion, headache, dizziness, ataxia, nausea, and prolonged
unconsciousness. In 14 patients, plasmapheresis was per-
formed, 11 for documented hyperviscosity, and an additional
three for unclear reasons.
Atherosclerosis was common among HLM patients
(Table S3) affecting more than a fourth of all patients (15
out of 50 cases with sufficient data). Typically, the coronary
arteries were involved (ten patients) followed by lower
limbs (four cases) and cerebral arteries (two cases). In
contrast to a predominance of atherosclerosis among cases
published before 1975 (14 out of 25 patients), it was much
less often observed within the last 30 years (four out of 25).
Treatment Anti-myeloma chemotherapy was applied in 33
patients (Table S4), two of which (including the present
case) were treated by autologous and allogeneic bone
marrow transplantation. In 14 patients, a partial or complete
response, typically for a limited time period was documented.
In all of these patients, the lipid levels markedly improved or
even normalized. Anti-myeloma treatment of six patients with
skin xanthomas induced complete normalization and marked
improvement of skin symptoms in two patients, respectively.
Pharmacological treatment of hyperlipidemia was reported in
19 patients (Table S5). Most commonly, fibrates were used
(total 13 cases, 11 with sufficient data) resulting in lipid
normalization in one and an improvement in seven patients.
Other drugs also resulted at best in a partial response (two
out of five for statins, three out of five for niacine, two out of
Table 1 (continued)
Year of
publication
Sex Agea Diagnosisb Paraprotein g/l TGL
(mmol/l)
Cholesterol
(mmol/l)
Reference Atherosclerosis Skin
xanthomas
1960 F 65 MM IgA ? n.a. 21.5 [3, 26, 36] MI yes, HTOD
1960 M n.a. MM IgA ? n.a. 24.1 [3, 26] ? yes, n.s.
1952 F 50 MM β-2 ? 8.2 15 [65] ? no
1950 M 55 MM n.a. ? 65.7 23.3 [7] MI yes, OD
1937 M 50 MM n.a. ? n.a. 9.2 [14] CVI no
MM multiple myeloma, sMM smoldering type multiple myeloma, MGUS monoclonal gammopathy of unknown significance, n.a. not available,
MI myocardial infarction, SCD sudden cardiac death, CVI cerebrovascular insult, PAD peripheral arterial disease, H hands (palmar surface or
palmar creases), K knee, E elbow, T trunk, F flexor folds, O periorbital, D diffuse skin involvement, P relation to pressure points (rings and
brassiere)
a Age at which the first diagnosis of plasma cell disease was made
b If different from final diagnosis, initial hematological diagnosis is given in brackets
c Biclonal myeloma, light chain lambda type was also found
d Concentration of class of antibody (IgA, IgG or IgM)
e Protein concentration of electrophoresis fraction (b or g) containing paraprotein
f Total protein concentration in serum
g IgA 16-fold upper limit of normal
Table 2 Characteristics of 53 patients with HLM. Median values and
95% confidence intervals are given
HLM Usual myeloma [35]
Male n=30 (57%) Slight male predominance
Female n=23 (43%)
Median age at diagnosis 55.3 years±3.1
Multiple myeloma 57.0 years±3 66 years
Smoldering myeloma 53 years±6.3
MGUS 49 years±7.8
IgG n=19 (42.2%) 51.5%
IgA n=24 (53.3%)* 21%
IgM n=1 (2.2%) 0.5%
IgD n=1 (2.2%) 2%
Kappa n=20 (57.1%)a 66.6%
Lambda n=15 (42.9%) 33.4%
* p=0.0006, significant difference compared to normal myeloma
cohort. Please note that in meta-analysis with incomplete data, p
values have to be interpreted with extreme caution
a not significant.
Ann Hematol (2010) 89:569–577 573
six for cholestyramin/cholestipol, and three out of four for
probucol).
Outcome Both, progression of myeloma and atypical
hyperlipidemia determined the outcome of the disease.
Twenty-five patients died, 11 of them because of myeloma
complications including infections (seven), renal failure
(three), and progression of myeloma (one). The causes of
death for 12 of the remaining patients were myocardial
infarction (five), sudden cardiac death (one), heart failure
(three), hyperviscosity syndrome (two), and pancreatitis (one).
A Kaplan–Meier estimation of median overall survival of
multiple myeloma patients with HLM (28 months) was
slightly shorter than in patients with normal multiple myeloma
(30 months). Median survival of patients with smoldering
myeloma or MGUS tended to be longer.
Pathophysiology The mechanisms leading to hyperlipidemia
in patients with HLM are not known. In general, hyperlipid-
emia might either be due to an increased lipid synthesis or
decreased lipid degradation. The half-life of lipids was tested
experimentally in six cases, four times in vivo using labeled
lipids, and twice in tissue culture. Uniformly, a prolonged
half-life for lipids was demonstrated suggesting decreased
lipid degradation as the mechanism causing hyperlipidemia.
Physical binding of paraprotein and lipoprotein was demon-
strated in 24 of 32 cases tested (Table 3). Co-migration in
electrophoresis (14/19) and ultracentrifugation (12/18) were
frequently employed to demonstrate complex formation.
Binding activity was found to be within the Fab fragment
of the antibody in all four cases tested. In five cases, the
paraprotein was purified and a complex of lipoproteins and
paraprotein was reconstituted with normal serum, suggesting
that properties of the paraprotein and not the lipoprotein were
responsible for the formation of this abnormal complex. In
contrast, in 12 of the 28 patients tested, evidence against
complex formation was found in at least one assay (Table 3).
Sometimes, different assays yielded contradictory results
within a single patient. Moreover, in a minority of patients,
no association of paraprotein and lipoprotein could be
documented at all and different pathophysiological mecha-
nisms were suggested: In some cases, lipolytic activity in the
serum after injection of heparin was found to be low
(Table 3). In two patients, the paraprotein had an affinity to
heparin, which is an essential co-factor for lipases. In another
case, blocking of the LDL receptor by the paraprotein
inhibited lipid degradation.
Discussion
Summarizing the available data for all reported cases of
HLM, the typical clinical presentation is characterized by
IgA myeloma, hyperlipidemia, and skin xanthomas of
palmar creases, hands and knees, and hyperviscosity which
may dominate the clinical picture. HLM can be associated
Complex formation of paraprotein and lipoprotein
Criteria Found Not found
Co-migration in electrophoresis 14 5
Ultracentrifugation 12 6
Gel filtration 4 2
Low speed centrifugation 5 1
Immunodiffusion 5 3
Othera 5 4
Evidence in at least one assay
For complex formation Against complex formation
All 24 (32 tested) 12 (32 tested)
Excluding electrophoresis 18 (25 tested) 10 (25 tested)
Post heparin lipolytic activity
Post heparin lipase activity Reduced 4b Normal 3
Specific activity of paraprotein
Anti-Heparin 2
Anti-LDL receptor 1
Table 3 Summary of experi-
ments describing the
mechanism of hyperlipidemia
in HLM. Patients with evidence
for complex formation have
higher cholesterol
concentrations (p=0.014)
than patients with evidence
against complex formation
a Other assays included LDL
sepharose, native western blot,
immunoprecipitation, immuno-
flourescence, immunofixation,
immunoelectrophoresis, and
rocket electrophoresis
b In most cases lipoprotein lipase
activity; in one case, hepatic
triglyceride lipase activity was
measured
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with artherosclerosis; however, since it was less frequently
diagnosed in recent years, we believe that overall better
treatment and prophylaxis may delay the onset of athero-
sclerosis. The best therapy for HLM has not been defined;
in most patients, pharmacological lipid-lowering therapy
was largely ineffective. In contrast, even partially successful
anti-myeloma chemotherapy resulted in clear improvement of
the lipid levels. In some cases, lipid values were conveniently
used as disease marker for HLM. The effect of anti-myeloma
chemotherapy on xanthomas was less impressive. Most likely,
reversing xanthomas requires a prolonged period with normal
or near normal lipid and paraprotein levels which was not
achieved in most patients.
HLM is considered to be an exceedingly rare clinical
entity. Indeed, in a large study, only 6% of 300 myeloma
patients tested had cholesterol levels above 7.76 mmol/
l including 1% above 12.9 mmol/l [34]. In the same study,
2% of 131 patients tested had triglyceride levels
>3.4 mmol/l, all of these values were elevated above
5.7 mmol/l. However, the most common lipid abnormality
of multiple myeloma seems to be a low cholesterol level: in
26% of the 300 patients the cholesterol levels were below
3.9 mmol/l; and 13% had cholesterol levels below
0.57 mmol/l [34]. Nevertheless, since lipid levels were
only reported in a subgroup of myeloma patients, lipid
abnormalities might be an underdiagnosed condition.
The mechanisms leading to hyperlipidemia are not entirely
clarified. In two-thirds of the patients tested, a complex
between paraprotein and lipoprotein was demonstrated. In
these cases, the antibody seems to cover the lipoprotein,
preventing steric access of lipases and reducing lipid
degradation. The epitopes recognized by the antibody are
largely unknown; in some cases, the paraprotein was able to
bind lipoproteins derived from a wide range of species (fish to
mammals, HDLs to VLDLs), suggesting unspecific binding
to universal components of lipoproteins. For other para-
proteins, the substrate range was more specific. The affinity of
the paraprotein to its lipoprotein target is most likely week: in
most cases, hyperlipidemia occurred while the paraprotein
concentration was high and resolution required lowering, but
not disappearance of the paraprotein. For unknown reasons,
the pathological process leading to hyperlipidemia seems to
be better supported by IgA than by IgG molecules. In a
minority of patients, complexes between paraprotein and
lipoproteins were not detected despite considerable experi-
mental efforts. On the one hand, a week or transient
interaction might have evaded detection, on the other hand,
a different mechanism might be responsible for hyperlipid-
emia in these patients. An inhibition of lipoprotein lipases,
possibly via an affinity towards the co-factor heparin was
proposed, as well as blocking of the cellular LDL receptor.
Complexes of lipoprotein and paraprotein might be more
common than appreciated. In some of the myeloma patients
with hypocholesterolemia, an affinity of paraprotein towards
lipoprotein was also demonstrated [38, 51, 57, 61]. It has been
speculated that the paraprotein opsonises the lipoprotein
followed by degradation by macrophages [50]. In one of
these studies, the serum of 20 patients with detectable affinity
of paraproteins to lipoproteins had significantly lower total
lipid values then the sera of 38 patients without this activity
[51]. It remains mysterious as to what features of the antibody
are increasing or decreasing the degradation of the lip-
oproteins in hyperlipidemic versus hypolipidemic myeloma.
In many aspects, patients with HLM mimic the disease
familial dysbetalipoproteinemia (FD). Patients suffering from
this condition also have elevated cholesterol and triglyceride
levels and develop similar skin xanthomas [59]. Lipid
electrophoresis demonstrates a typical broad beta peak in
FD patients. Even though documentation was incomplete, at
least 15 reported patients with HLM revealed a similar
electrophoretic pattern. However, FD is not known to be
associated with multiple myeloma and responds promptly to
lipid-lowering therapy. The genotype E2/E2 or rare muta-
tions of the apolipoprotein E (ApoE) gene are responsible for
FD. ApoE is present on LDLs and serves as a co-receptor for
the LDL receptor. The affinity of the ApoE2 allele to its
receptor is 100-fold weaker, causing a reduced uptake of
LDL and, consequently, accumulation of lipoproteins.
However, only a fraction of patients with this genotype
develops hyperlipidemia, typically in association with other
diseases such as diabetes mellitus or hypothyroidism. The
ApoE genotype was tested in nine patients with HLM, two
were homozygous for E2, and five heterozygous. In contrast,
the frequencies for the E2/E2 and E2/E3 genotypes in the
normal population are 1% and 10%, respectively. It is
tempting to speculate that covering of the lipoproteins with
antibodies in the setting of a partially or completely deficient
LDL co-receptor causes hyperlipidemia. However, in the two
patients (including ours) that were of the E3/E3 genotype,
other so far unrecognized pathogenetic mechanisms must be
responsible for hyperlipidemia.
In summary, the association of multiple myeloma and
hyperlipidemia is a rare but clinically relevant and scientifi-
cally fascinating condition. Since many features of the disease
remain unresolved, further work with systematic biochemical
experiments in a larger series of patients is needed. These
biochemical data in combination with clinical and genetic data
might clarify the mechanism of this association.
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